Your browser is no longer supported. Please, upgrade your browser.
BHVN Biohaven Pharmaceutical Holding Company Ltd. monthly Stock Chart
BHVN [NYSE]
Biohaven Pharmaceutical Holding Company Ltd.
Index- P/E- EPS (ttm)-8.95 Insider Own11.10% Shs Outstand49.88M Perf Week13.35%
Market Cap2.35B Forward P/E- EPS next Y-5.87 Insider Trans-1.51% Shs Float44.10M Perf Month23.73%
Income-389.60M PEG- EPS next Q-1.57 Inst Own94.10% Short Float13.61% Perf Quarter-25.33%
Sales- P/S- EPS this Y-23.00% Inst Trans23.55% Short Ratio5.66 Perf Half Y-6.13%
Book/sh4.13 P/B11.39 EPS next Y36.40% ROA-127.60% Target Price75.63 Perf Year21.97%
Cash/sh9.34 P/C5.04 EPS next 5Y- ROE-311.30% 52W Range29.17 - 67.86 Perf YTD27.18%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-28.59% Beta-
Dividend %- Quick Ratio10.60 Sales past 5Y- Gross Margin- 52W Low66.13% ATR2.14
Employees63 Current Ratio10.60 Sales Q/Q- Oper. Margin- RSI (14)71.93 Volatility5.37% 4.95%
OptionableYes Debt/Eq0.51 EPS Q/Q-362.80% Profit Margin- Rel Volume2.35 Prev Close47.03
ShortableYes LT Debt/Eq0.51 Earnings- Payout- Avg Volume1.06M Price48.46
Recom1.70 SMA2020.52% SMA5016.92% SMA2005.19% Volume404,682 Change3.04%
Jun-25-19Reiterated Canaccord Genuity Buy $89 → $84
May-06-19Initiated Goldman Buy $92
Apr-09-19Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-04-19Reiterated Needham Buy $48 → $56
Jul-03-18Reiterated Needham Buy $36 → $48
Jul-02-18Reiterated Needham Buy $36 → $48
Apr-05-18Downgrade Barclays Overweight → Equal Weight $30 → $25
Feb-22-18Reiterated Canaccord Genuity Buy $30 → $39
Dec-15-17Initiated Canaccord Genuity Buy $30
Oct-03-17Reiterated Needham Buy $43 → $36
Sep-10-19 07:30AM  Biohaven Advances NOJECTION Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine PR Newswire
Sep-09-19 07:30AM  Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session PR Newswire
Aug-08-19 05:02PM  Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments PR Newswire
Aug-07-19 07:30AM  Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial PR Newswire
Jul-31-19 07:30AM  Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy PR Newswire
Jul-24-19 04:30AM  Release Your 'Inner Spock' When Investing in Biotech Stocks TheStreet.com
Jul-22-19 07:30AM  Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled PR Newswire
Jul-19-19 06:59PM  Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod Reuters
06:10PM  Biohaven's Nurtec (riluzole) 505(b)2 Application for Amyotrophic Lateral Sclerosis Affected by Issues Related to Apotex Plant: Complete Response Letter (CRL) Received From FDA Related to Isolated Drug Substance Supply Used in Bioequivalence Study PR Newswire
Jul-15-19 10:22AM  Biohaven reveals positive results in migrane drug trial Yahoo Finance Video +7.53%
07:30AM  Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet PR Newswire
Jul-11-19 07:30AM  Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety PR Newswire
07:30AM  Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine PR Newswire
06:17AM  The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug Benzinga
Jul-10-19 05:00PM  Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine PR Newswire
04:30AM  2 Single Hitters That Could Score With the 'Write' Strategy TheStreet.com
Jul-05-19 02:05PM  Biohaven Offering Seems to Make Sale Less Likely GuruFocus.com
Jul-02-19 12:15PM  Weekly CFO Buys Highlight GuruFocus.com
Jul-01-19 07:30AM  Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia PR Newswire
Jun-26-19 11:15PM  Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Bought $201,100 of Shares GuruFocus.com +5.60%
Jun-24-19 07:30AM  Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor Antagonist PR Newswire
Jun-18-19 10:07PM  Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares PR Newswire -23.61%
01:05PM  Migraine-Drug Deal Hype Turns Into a Giant Headache Bloomberg
12:40PM  Here's Why Biohaven Pharmaceutical Plummeted Today Motley Fool
07:31AM  The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga
07:05AM  Should Biohaven Pharmaceutical Holding (NYSE:BHVN) Be Disappointed With Their 36% Profit? Simply Wall St.
Jun-17-19 06:00PM  Biohaven Announces Proposed Public Offering Of Common Shares PR Newswire -8.92%
Jun-14-19 12:03PM  Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures Investor's Business Daily
Jun-11-19 01:50PM  Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Insider Monkey
11:53AM  Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock Zacks
May-07-19 11:30PM  Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP-Targeting Monoclonal Antibodies PR Newswire
11:15PM  Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms PR Newswire
06:55AM  Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms PR Newswire
May-03-19 07:30AM  Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor Event PR Newswire
May-02-19 01:21PM  These 6 biotech stocks are promising takeover targets MarketWatch
12:41PM  Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Insider Monkey
Apr-26-19 06:10AM  Analysts point to potential Biogen M&A options after Alzheimer's failure American City Business Journals
Apr-16-19 08:10AM  The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives Benzinga
Apr-15-19 08:43AM  Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options Zacks
Apr-12-19 06:24PM  Here's Why Biohaven Pharmaceutical Jumped 20% Today Motley Fool +19.96%
06:14PM  CBX: Strong earnings for financials a good start CNBC Videos
04:30PM  General Electric, Biohaven Pharmaceutical Holding, Tesla and More Are Trending Insider Monkey
Apr-03-19 07:30AM  Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience PR Newswire
Apr-01-19 07:30AM  Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine PR Newswire
Mar-18-19 07:30AM  Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application PR Newswire
Mar-14-19 07:15PM  Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Sold $5 million of Shares GuruFocus.com
12:52PM  Has Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Got Enough Cash? Simply Wall St.
07:30AM  Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole PR Newswire
Mar-13-19 07:30AM  Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant PR Newswire
Mar-05-19 07:40AM  Factors of Influence in 2019, Key Indicators and Opportunity within Expedia Group, Lumentum, Patterson Companies, Allscripts Healthcare Solutions, AtriCure, and Biohaven Pharmaceutical Holding New Research Emphasizes Economic Growth GlobeNewswire
Feb-28-19 04:30PM  Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results PR Newswire
Feb-21-19 10:00AM  What Makes Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a Strong Momentum Stock: Buy Now? Zacks
Feb-20-19 07:30AM  Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole PR Newswire
Feb-19-19 07:30AM  Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy PR Newswire
Feb-04-19 07:30AM  Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist PR Newswire
Jan-23-19 07:22AM  The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study Benzinga
03:00AM  Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy PR Newswire
Jan-07-19 03:00AM  Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China PR Newswire
Jan-03-19 07:30AM  Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire -5.34%
Dec-17-18 07:08PM  Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
Dec-12-18 10:56PM  Biohaven Announces Pricing of Public Offering of Common Shares PR Newswire
Dec-10-18 07:19PM  Biohaven Announces Proposed Public Offering of Common Shares PR Newswire
03:00AM  Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study PR Newswire
Dec-03-18 03:00AM  Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine PR Newswire +25.39%
Nov-29-18 08:09AM  The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved Benzinga
Nov-28-18 04:00PM  Biohaven Announces Formation Of BioShin, A Wholly Owned Asia-Pacific Subsidiary PR Newswire
Nov-27-18 08:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Dillard's, Biohaven Pharmaceutical Holding, HTG Molecular Diagnostics, Strongbridge Biopharma, Myriad Genetics, and Beazer Homes New Research Emphasizes Economic Growth GlobeNewswire -7.69%
Nov-26-18 03:00AM  Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire
Nov-20-18 03:00AM  Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018 PR Newswire
Nov-15-18 03:00AM  Biohaven Enrolls First Patient In Phase 3 Preventive Treatment Of Migraine Trial With Its Oral CGRP Receptor Antagonist Rimegepant PR Newswire
Nov-14-18 04:06PM  Migraine-Focused Biotech Has A Headache On Quarterly Losses Investor's Business Daily -8.73%
03:00AM  Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results PR Newswire
Nov-13-18 08:30AM  Kleo Pharmaceuticals Secures $21 Million to Advance Novel Small Molecule Cancer Immunotherapies PR Newswire
Oct-22-18 03:00AM  Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist PR Newswire
Oct-10-18 02:42PM  Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-09-18 03:00AM  Biohaven Acquires Option To License Biologic Investigational Agent For Inflammatory And Autoimmune Diseases From The University of Connecticut PR Newswire
Sep-12-18 06:19AM  Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine PR Newswire +6.40%
03:00AM  Biohaven Appoints Bob Repella to Board of Directors PR Newswire
Sep-06-18 03:00AM  Biohaven Presents at Migraine Trust International Symposium and Highlights Positive Results from Study 301 and Study 302 of Rimegepant, an Oral CGRP Receptor Antagonist, in the Acute Treatment of Migraine PR Newswire
Sep-05-18 08:28AM  The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga
03:00AM  Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy PR Newswire
Aug-16-18 09:37AM  The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait Benzinga +5.95%
Aug-14-18 04:15PM  Biohaven Pharmaceuticals Reports Second Quarter 2018 Financial And Recent Business Results PR Newswire
Aug-01-18 07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Protagonist Therapeutics, HD Supply, BIOHAVEN PHARM, Big Lots, Clean Energy Fuels, and H&E Equipment Services New Research Emphasizes Economic Growth GlobeNewswire
03:00AM  First Patient Enrolled In Biohaven's Phase 2/3 Mild-To-Moderate Alzheimer's Clinical Trial PR Newswire
Jul-31-18 07:15AM  Free Stock Performance Review on Biogen and Three Additional Biotech Stocks ACCESSWIRE
Jul-24-18 03:00AM  Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease PR Newswire
Jun-28-18 12:30PM  Biohaven Pharma's New Migraine Drug Shows Promise in Late-Stage Test Results TheStreet.com
07:20AM  Free Technical Reports on Cerus and Three Additional Biotech Equities ACCESSWIRE
03:00AM  Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting PR Newswire
Jun-21-18 07:15AM  Blog Exposure - Biohaven Signs Royalty Funding and Stock Purchase Agreements with Royalty Pharma ACCESSWIRE
Jun-19-18 08:37AM  Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) Is Expected To Breakeven Simply Wall St.
Jun-18-18 08:06PM  Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million PR Newswire
Jun-13-18 07:30AM  Biohaven CEO Vlad Coric Named Ernst & Young Entrepreneur Of The Year 2018 Award Winner in New York Region PR Newswire
Jun-05-18 03:00AM  Biohaven to Present Key and Expanded Data from Phase 3 Clinical Trials of Rimegepant, its Oral CGRP Receptor Antagonist, During Four Late-Breaking Sessions at American Headache Society (AHS) Annual Scientific Meeting 2018 PR Newswire
May-16-18 08:35AM  What Do Analysts Think About Biohaven Pharmaceutical Holding Company Ltds (NYSE:BHVN) Earnings Trend? Simply Wall St.
May-15-18 04:15PM  Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results PR Newswire
May-09-18 07:35AM  Our Free Research Report on Biogen and More Biotech Stocks ACCESSWIRE
03:00AM  Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS) PR Newswire
Apr-22-18 10:00PM  Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine PR Newswire
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AGUIAR ERICDirectorSep 11Option Exercise25.5110,000255,10010,000Sep 13 04:34 PM
AGUIAR ERICDirectorSep 11Sale45.0010,000450,0000Sep 13 04:34 PM
Bailey GregoryDirectorAug 20Buy37.655,000188,2502,587,601Aug 21 04:11 PM
Engelhart JamesChief Financial OfficerJun 27Buy43.052,500107,6252,500Jun 28 07:11 AM
Berman RobertChief Medical OfficerJun 27Buy42.302,500105,750240,500Jun 28 07:09 AM
Coric VladChief Executive OfficerJun 26Buy40.225,000201,10019,130Jun 26 09:28 PM
CHILDS JOHN WDirectorJun 26Buy40.3710,000403,70010,000Jun 26 08:40 PM
Doogan DeclanDirectorApr 16Sale61.9250,0003,096,000926,002Apr 16 07:23 PM
Doogan DeclanDirectorApr 12Sale53.9238,8252,093,444976,002Apr 16 07:23 PM
Doogan DeclanDirectorMar 26Sale53.725,824312,8651,014,827Mar 26 06:30 PM
Bailey GregoryDirectorMar 25Option Exercise9.29107,500998,6752,582,601Apr 05 05:54 PM
CHILDS JOHN WDirectorMar 22Option Exercise9.29107,500998,675107,500Apr 05 05:53 PM
Doogan DeclanDirectorMar 22Sale53.665,351287,1351,020,651Mar 26 06:30 PM
Coric VladChief Executive OfficerMar 14Sale50.0231,8931,595,446440,000Mar 14 05:49 PM
Coric VladChief Executive OfficerMar 13Sale50.0216,145807,573455,783Mar 14 05:49 PM
Tilton JohnChief Commercial OfficerMar 12Option Exercise9.2910,00092,90010,000Mar 14 05:51 PM
Coric VladChief Executive OfficerMar 12Sale50.1551,9622,605,894464,045Mar 14 05:49 PM
Tilton JohnChief Commercial OfficerMar 12Sale50.1110,000501,1000Mar 14 05:51 PM
Doogan DeclanDirectorMar 01Sale47.1750,5952,386,5191,026,002Mar 01 05:59 PM
Doogan DeclanDirectorFeb 27Sale45.7123,3841,068,8831,076,597Mar 01 05:59 PM
Doogan DeclanDirectorFeb 27Sale45.0227,0451,217,520373,913Mar 01 05:59 PM
Doogan DeclanDirectorFeb 26Sale44.3120,896925,952400,958Feb 26 05:44 PM
Doogan DeclanDirectorFeb 25Sale45.4913,943634,2671,099,981Feb 26 05:44 PM
Doogan DeclanDirectorFeb 25Sale45.2520,434924,688421,854Feb 26 05:44 PM
Doogan DeclanDirectorFeb 22Sale44.7521,625967,682442,288Feb 26 05:44 PM
GREGORY JULIA PDirectorFeb 21Option Exercise23.6312,000283,56012,000Feb 25 04:40 PM
GREGORY JULIA PDirectorFeb 21Sale43.5612,000522,7200Feb 25 04:40 PM
Doogan DeclanDirectorFeb 19Sale45.511,40063,7141,113,924Feb 20 05:40 PM
Doogan DeclanDirectorFeb 15Sale45.4267830,7951,115,324Feb 20 05:40 PM
AGUIAR ERICDirectorFeb 04Option Exercise23.4717,609413,29117,609Feb 06 06:21 PM
Tilton JohnChief Commercial OfficerJan 10Option Exercise9.2910,50097,54510,500Jan 14 05:50 PM
Tilton JohnChief Commercial OfficerJan 10Sale37.6710,500395,5350Jan 14 05:50 PM
Doogan DeclanDirectorDec 03Sale41.9540,0001,678,0001,156,002Dec 06 04:26 PM